#Osteoporosis #Biotech #ClinicalTrials
www.benzinga.com
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
- Company expects topline data from the study in 2027
WESTLAKE VILLAGE, Calif.
#Biopharma #Neuroscience #ClinicalTrials
www.benzinga.com
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Neumora Therapeutics (NASDAQ:NMRA)
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation
KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026
Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model
Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score
Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027
WATERTOWN, Mass.
#Pharmaceuticals #ClinicalTrials #EndocrineDiseases
www.benzinga.com
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Crinetics Pharmaceuticals (NASDAQ:CRNX)
SAN DIEGO, Jan.
C
#CancerResearch #PancreaticCancer #ClinicalTrials
www.courant.com
Pancreatic cancer is among the deadliest cancers. A new drug being tested at Penn is giving patients and doctors hope
PHILADELPHIA -- Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to stage 4 less than a year after her initial diagnosis.
#Gonorrhea #AntibioticResistance #ClinicalTrials
www.sciencedaily.com
New antibiotic pill shows promise against drug-resistant gonorrhea
Researchers are testing a new oral medication called zoliflodacin that could offer a simpler way to treat gonorrhea, especially strains that no longer respond well to existing antibiotics.
